Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elamipretide Topical Ophthalmic Solution in LHON
NCT02693119Phase 2Completed
- Sponsor
- Stealth BioTherapeutics
- Start
- Mar 2016
- Primary completion
- Sep 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of elamipretide in Leber hereditary optic neuropathy (LHON) (4 arms), sponsored by Stealth BioTherapeutics. Primary endpoints: Incidence of Ocular Treatment-Emergent Adverse Events at 160 weeks, Severity of Ocular Treatment-Emergent Adverse Events at 160 weeks and 1 more. Started Mar 2016; status: completed.
02
Drugs
elamipretide
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on NCT02693119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02693119.